Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis - Full Text View

Purpose

Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

Condition	Intervention	Phase
Plaque Psoriasis	Drug: Clobetasol Propionate, 0.05% Drug: Calcipotriene and betamethasone dipropionate ointment	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment
Official Title:	An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis

Resource links provided by NLM:

MedlinePlus related topics: Psoriasis

Drug Information available for: Betamethasone Betamethasone dipropionate Clobetasol propionate Calcipotriene Daivobet

U.S. FDA Resources

Further study details as provided by Galderma Laboratories, L.P.:

Primary Outcome Measures:

Overall Disease Severity [ Time Frame: End of treatment (Week 4) ]
Tolerability assessments, incidence of adverse events [ Time Frame: Baseline, Weeks 1, 2, 4 and 8 ]

Secondary Outcome Measures:

Overall Disease Severity [ Time Frame: Weeks 1, 2 and 8 ]
Investigator Global Assessment [ Time Frame: End of treatment (week 4) and Weeks 1, 2 and 8 ]


Enrollment:	122
Study Start Date:	August 2006
Study Completion Date:	June 2007
Primary Completion Date:	June 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 Clobex® Spray	Drug: Clobetasol Propionate, 0.05% Topical, twice daily for 4 weeks Other Name: Clobex® Spray
Active Comparator: 2 Taclonex® Ointment	Drug: Calcipotriene and betamethasone dipropionate ointment Topical, once daily Other Name: Taclonex® Ointment

Detailed Description:

Same as above.

Eligibility


Ages Eligible for Study:	18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Moderate to severe psoriasis involving 3-20% of the body surface area

Exclusion Criteria:

Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment
Subjects having psoriasis that involves the scalp, face, or groin

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00437255

Locations


United States, Minnesota
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
United States, Texas
DermResearch, Inc.
Austin, Texas, United States, 78759
J & S Studies, Inc.
Bryan, Texas, United States, 77802
Baylor Research Institute
Dallas, Texas, United States, 75230

Sponsors and Collaborators

Galderma Laboratories, L.P.

Investigators


Study Director:	Ronald W Gottschalk, MD	Galderma Laboratories, LP

More Information


Responsible Party:	Ronald W. Gottschalk, MD / Medical Director, Galderma Laboratories, L.P.
ClinicalTrials.gov Identifier:	NCT00437255 History of Changes
Other Study ID Numbers:	US10034
Study First Received:	February 16, 2007
Last Updated:	April 3, 2008

Additional relevant MeSH terms:


Psoriasis Skin Diseases, Papulosquamous Skin Diseases Betamethasone-17,21-dipropionate Betamethasone benzoate Clobetasol Betamethasone Betamethasone Valerate Betamethasone sodium phosphate Calcipotriene Calcitriol Anti-Inflammatory Agents Glucocorticoids Hormones	Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Dermatologic Agents Calcium Channel Agonists Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Vasoconstrictor Agents Vitamins Micronutrients Growth Substances Bone Density Conservation Agents Anti-Asthmatic Agents Respiratory System Agents

ClinicalTrials.gov processed this record on June 28, 2017